ABBVIE INC.ABBV
Closing prices as of Oct 5, 2026Updated once daily after the US close — not a live quote.

$265.11

+4.41% past month

Notable price movement

  • Oct 5, 2026

    $265.76+1.12%

  • Oct 2, 2026

    $262.82+1.11%

  • Oct 1, 2026

    $259.93-0.63%

    Comparable pharmaceutical companies fell 1.77% on average, with all six of the six falling . AbbVie's decline of 0.63% was smaller than the cohort's . Seeking Alpha reported long-term phase 3 data showing continued vitiligo repigmentation with Rinvoq through week 76 .

  • Sep 30, 2026

    $261.59-0.65%

    Comparable pharmaceutical companies fell 1.60% on average, with all six falling . AbbVie's decline was smaller than that of the group. Seeking Alpha reported Phase 1 weight-loss data for ABBV-295 and positive phase 2 data for zumilokibart in atopic dermatitis .

  • Sep 29, 2026

    $263.29-1.12%

  • Sep 28, 2026

    $266.28+0.73%

    Seeking Alpha reported that AbbVie's Juvmo won FDA approval for Parkinson's disease . The shares closed up 0.73% that day.

  • Sep 25, 2026

    $264.34-0.29%

Closing prices for ABBV. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Recent news

Seeking Alpha23 hours agoAbbVie flags $216M IPR&D and milestones expense for Q3The Motley Fool1 day agoWhy I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October24/7 Wall St5 days ago5 Solid Dividend Stocks to Buy NowSeeking Alpha1 day agoGenmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatmentThe Motley Fool3 days agoAbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.Seeking Alpha1 day agoRegenxbio a new Outperform at Mizuho on potential of two pipeline drugs

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.

Prices and financial data are historical and provided for research only. Not investment advice.